Navigation Links
A new jump start for aging blood vessels

Recent studies show promise for significantly reducing vascular aging by inactivating TNFa, which has been linked to blood vessel dysfunction and cell death. The related report by Csiszar et al., "Vasculoprotective effects of anti-TNFa treatment in aging," appears in the January issue of The American Journal of Pathology.

Age-related vascular diseases, including high blood pressure, heart attack and stroke, occur naturally, even in otherwise healthy individuals. Advanced age is also associated with increased levels of TNFa, a protein that can attack and destroy tumor cells but can also exacerbate chronic inflammatory diseases. To date, no studies have investigated the potential beneficial effects of TNFa inhibition in vascular aging, making this the first study of its kind.

Csiszar and collegues treated aged rats with etanercept to test the hypothesis that anti-TNFa treatment exerts vasculoprotective effects in aging. Etanercept (Enbrel) is an FDA-approved drug that binds and inactivates circulating TNFa. Recent studies have demonstrated that anti-TNFa therapies, including etanercept, may improve inflammation-related vascular disease, including heart failure.

Csiszar and colleagues made four notable findings in their study. First, they confirmed that in advanced aging, increased TNFa levels were associated with significant impairment of vessel relaxation, which is required for proper regulation of blood pressure.

Second, blocking TNFa via chronic etanercept treatment decreased cell death in aged vessels, demonstrating that increased TNFa levels likely contribute to age-related cardiovascular disease. Similar cell-protective effects were found when anti-TNFa antibodies were used in cell culture.

Third, not only was TNFa released into the blood, where it can have systemic effects, but it is also expressed within blood vessel walls, where it can exert specific local effects.

Lastly, administration of TNFa to young arteries reproduced the features of vascular aging, such as blood vessel dysfunction and cell death, further confirming the role of TNFa in the aging of the cardiovascular system.

The knowledge that cardiovascular disease is the leading cause of death for both men and women in the U.S. underscores the significance of these findings. This treatment could one day lead us closer to better heart health as we age.
'"/>

Source:American Journal of Pathology


Related biology news :

1. Jump-starting T Cells In Skin Cancer
2. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
3. Nanotechnology may find disease before it starts
4. Suicide risk does not increase when adults start using antidepressants, study finds
5. When the going gets tough, slime molds start synthesizing
6. Whiplash injuries ?are they caused by startle reflexes?
7. Gardenia fruit compound starting point for diabetes therapy
8. Epstein-Barr virus might kick-start multiple sclerosis
9. Human stem cells delay start of Lou Gehrigs disease in rats
10. Air travel and flu: Post-9/11 restrictions delayed start of season
11. A healthier start to a pigs life

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2016)... 18, 2016  Extenua Inc., a pioneering developer ... use and access of ubiquitous on-premise and cloud ... American Cyber.  ... transformational C4ISR and Cyber initiatives in support of ... proven technology solutions," said Steve Visconti , ...
(Date:1/11/2016)... Synaptics Incorporated (NASDAQ: SYNA ), the ... its ClearPad ® TouchView ™ 4300 touch ... categories in the 8 th Annual Mobile Excellence ... The Synaptics ® TDDI solution enables faster time-to-market, ... devices, brighter displays and borderless designs. ...
(Date:1/7/2016)... -- This BCC Research report studies the global as ... identifying newer markets and exploring the expansion of the ... Includes forecast from 2015 to 2020. Use ... the expansion of the present application market for various ... technology, determine its current market size, and estimate the ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... SHELTON, Conn. , Feb. 8, 2016  NanoViricides, Inc. (NYSE ... that its CEO, Eugene Seymour , MD, MPH, will present ... 5:30PM at the Waldorf-Astoria Hotel in New York City ... presentation will be in the Windsor Room at 5:30PM EST. Registered ... New York City . --> ...
(Date:2/8/2016)... --> --> ... Point-Of-Care (POC) molecular diagnostics company, today announces that it has ... to be launched on the Company,s io® platform. By meeting ... is now cleared for sale within the European Union. ... the io® CT test signals a new era in ultra-rapid ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the premier ... to assist the medical and life science researchers that ... Virus infection.   CDC website . ... Zika virus is a single-stranded RNA virus of ... West Nile, Dengue and Chikungunya Viruses. Zika virus is ...
(Date:2/5/2016)... 5, 2016 Amarantus BioScience Holdings, ... focused on developing products for Regenerative Medicine, Neurology and ... Disease Designation (RPDD) from the US Food and Drug ... MANF was previously granted orphan drug designation (ODD) by ... Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), ...
Breaking Biology Technology: